Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis

被引:47
|
作者
Matuszczak, Milena [1 ]
Schalken, Jack A. [2 ]
Salagierski, Maciej [1 ]
机构
[1] Univ Zielona Gora, Coll Med, Dept Urol, PL-65046 Zielona Gora, Poland
[2] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 GA Nijmegen, Netherlands
关键词
cancer biomarkers; prostate cancer; liquid biopsy; prognosis; diagnosis; early detection; ANTIGEN; 3; PCA3; HEALTH INDEX; URINARY PCA3; SIGNIFICANTLY IMPROVES; 4-KALLIKREIN PANEL; EPIGENETIC ASSAY; ISOFORM P2PSA; MEN; RISK; PREDICT;
D O I
10.3390/cancers13133373
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary In prostate cancer, overdiagnosis and overtreatment is a common problem for clinicians. Accurate diagnosis and prognosis are essential to avoid unnecessary biopsy and to increases the effectiveness of treatment. A new, easy-to-use and non-invasive test based on liquid biopsy biomarkers such as Progensa PCA3, MyProstateScore, ExoDx, SelectMDx, PHI, 4K, Stockholm3 and ConfirmMDx have been developed to improve diagnosis, prognosis and to help guide the decision-making process. This article provides an overview of the above-mentioned commercial tests. The performance and financial aspects of the tests have been compared using available studies. Then the application of biomarker tests as an adjunct to multiparametric MRI in the diagnosis, prognosis and monitoring of prostate cancer has been discussed. Prostate cancer (PCa) is the most common cancer in men worldwide. The current gold standard for diagnosing PCa relies on a transrectal ultrasound-guided systematic core needle biopsy indicated after detection changes in a digital rectal examination (DRE) and elevated prostate-specific antigen (PSA) level in the blood serum. PSA is a marker produced by prostate cells, not just cancer cells. Therefore, an elevated PSA level may be associated with other symptoms such as benign prostatic hyperplasia or inflammation of the prostate gland. Due to this marker's low specificity, a common problem is overdiagnosis, which leads to unnecessary biopsies and overtreatment. This is associated with various treatment complications (such as bleeding or infection) and generates unnecessary costs. Therefore, there is no doubt that the improvement of the current procedure by applying effective, sensitive and specific markers is an urgent need. Several non-invasive, cost-effective, high-accuracy liquid biopsy diagnostic biomarkers such as Progensa PCA3, MyProstateScore ExoDx, SelectMDx, PHI, 4K, Stockholm3 and ConfirmMDx have been developed in recent years. This article compares current knowledge about them and their potential application in clinical practice.
引用
收藏
页数:29
相关论文
共 50 条
  • [21] New biomarkers for diagnosis and prognosis of localized prostate cancer
    Chistiakov, Dimitry A.
    Myasoedova, Veronika A.
    Grechko, Andrey V.
    Melnichenko, Alexandra A.
    Orekhov, Alexander N.
    SEMINARS IN CANCER BIOLOGY, 2018, 52 : 9 - 16
  • [22] Gene methylation biomarkers in diagnosis and prognosis of prostate cancer
    Bialkowska-Hobrzanska, H
    Wu, Y
    Driman, D
    Al-Omar, M
    Razvi, H
    JOURNAL OF UROLOGY, 2003, 169 (04): : 60 - 60
  • [23] Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer
    Mazzola, C. R. E.
    Ghoneim, T.
    Shariat, S. F.
    PROGRES EN UROLOGIE, 2011, 21 (01): : 1 - 10
  • [24] Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer
    Hirahata, Tetsuyuki
    ul Quraish, Reeshan
    ul Quraish, Afraz
    ul Quraish, Shahan
    Naz, Munazzah
    Razzaq, Mohammad Abdul
    CANCER INFORMATICS, 2022, 21
  • [25] Circulating Biomarkers of Colorectal Cancer (CRC)-Their Utility in Diagnosis and Prognosis
    Lukaszewicz-Zajac, Marta
    Mroczko, Barbara
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (11)
  • [26] Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer
    Hirahata, Tetsuyuki
    ul Quraish, Reeshan
    ul Quraish, Afraz
    ul Quraish, Shahan
    Naz, Munazzah
    Razzaq, Mohammad Abdul
    CANCER INFORMATICS, 2022, 21
  • [27] Clinical utility of current biomarkers for prostate cancer detection
    Kim, Jeong Hyun
    Hong, Sung Kyu
    INVESTIGATIVE AND CLINICAL UROLOGY, 2021, 62 (01) : 1 - 13
  • [28] Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis
    Pang, Bairen
    Zhu, Ying
    Ni, Jie
    Thompson, James
    Malouf, David
    Bucci, Joseph
    Graham, Peter
    Li, Yong
    THERANOSTICS, 2020, 10 (05): : 2309 - 2326
  • [29] The Future of Prostate Cancer Diagnosis: Biomarkers, Biopsy, Both, or Neither?
    Briganti, Alberto
    Giannarini, Gianluca
    Klatte, Tobias
    Catto, James W.
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY FOCUS, 2015, 1 (02): : 97 - 98
  • [30] Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer
    Dathathri, Eshwari
    Isebia, Khrystany T.
    Abali, Fikri
    Lolkema, Martijn P.
    Martens, John W. M.
    Terstappen, Leon W. M. M.
    Bansal, Ruchi
    FRONTIERS IN ONCOLOGY, 2022, 12